JP2002534083A - 骨髄機能廃絶性ではない寛容原性の処置 - Google Patents

骨髄機能廃絶性ではない寛容原性の処置

Info

Publication number
JP2002534083A
JP2002534083A JP2000592399A JP2000592399A JP2002534083A JP 2002534083 A JP2002534083 A JP 2002534083A JP 2000592399 A JP2000592399 A JP 2000592399A JP 2000592399 A JP2000592399 A JP 2000592399A JP 2002534083 A JP2002534083 A JP 2002534083A
Authority
JP
Japan
Prior art keywords
cells
donor
mammal
host
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000592399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002534083A5 (enExample
Inventor
シモン スラビン，
タチャナ プリゴジーナ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of JP2002534083A publication Critical patent/JP2002534083A/ja
Publication of JP2002534083A5 publication Critical patent/JP2002534083A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000592399A 1998-12-31 1999-12-23 骨髄機能廃絶性ではない寛容原性の処置 Pending JP2002534083A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/222,011 US6428782B1 (en) 1997-05-23 1998-12-31 Non-myeloablative tolerogenic treatment
US09/222,011 1998-12-31
PCT/US1999/030704 WO2000040701A2 (en) 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment

Publications (2)

Publication Number Publication Date
JP2002534083A true JP2002534083A (ja) 2002-10-15
JP2002534083A5 JP2002534083A5 (enExample) 2007-02-22

Family

ID=22830367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000592399A Pending JP2002534083A (ja) 1998-12-31 1999-12-23 骨髄機能廃絶性ではない寛容原性の処置

Country Status (6)

Country Link
US (1) US6428782B1 (enExample)
EP (3) EP1141246A2 (enExample)
JP (1) JP2002534083A (enExample)
CA (1) CA2356434A1 (enExample)
IL (1) IL143485A0 (enExample)
WO (1) WO2000040701A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
JP3734461B2 (ja) 2001-08-08 2006-01-11 松下電器産業株式会社 ライセンス情報変換装置
US20040151700A1 (en) * 2001-10-30 2004-08-05 Harlan David M. Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510456A (ja) * 1994-03-17 1997-10-21 バクスター、インターナショナル、インコーポレイテッド 同種リンパ球による癌の免疫療法
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
WO1998052582A2 (en) * 1997-05-23 1998-11-26 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
AU679437B2 (en) 1992-01-08 1997-07-03 General Hospital Corporation, The Induced tolerance to xenografts
US5876708A (en) 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
WO1995003062A1 (en) 1993-07-21 1995-02-02 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5514364A (en) 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510456A (ja) * 1994-03-17 1997-10-21 バクスター、インターナショナル、インコーポレイテッド 同種リンパ球による癌の免疫療法
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
WO1998052582A2 (en) * 1997-05-23 1998-11-26 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010001581, 今日の移植（１９９２），Ｖｏｌ．５，Ｎｏ．３，ｐ．３１７−３２２ *

Also Published As

Publication number Publication date
US6428782B1 (en) 2002-08-06
IL143485A0 (en) 2002-04-21
WO2000040701A2 (en) 2000-07-13
WO2000040701A3 (en) 2000-12-21
EP1141246A2 (en) 2001-10-10
WO2000040701A9 (en) 2001-09-13
CA2356434A1 (en) 2000-07-13
EP1498136A8 (en) 2005-04-13
EP1498479A2 (en) 2005-01-19
EP1498136A2 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
Pelot et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen
US6877514B2 (en) Mixed chimerism and tolerance
US8734786B2 (en) Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
Mehta et al. Graft-versus-myeloma
US20150104471A1 (en) Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
Mapara et al. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism1
HARDY et al. Pancreatic islet transplantation: induction of graft acceptance by ultraviolet irradiation of donor tissue
US6428782B1 (en) Non-myeloablative tolerogenic treatment
US6447767B1 (en) Non-myeloablative tolerogenic treatment
Gibbons et al. Manipulating the immune system for anti‐tumor responses and transplant tolerance via mixed hematopoietic chimerism
Sykes Mechanisms of tolerance
Yin et al. Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy1
US20060140912A9 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
EP0983074B1 (en) Non-myeloablative tolerogenic treatment
Cutler et al. Neonatally tolerant rats actively eliminate donor‐specific lymphocytes despite persistent chimerism
JP3553941B2 (ja) 異種移植片の胸腺
WO1995021527A1 (en) Stem cell engraftment
Martin et al. Engraftment, Graft Rejection, and Graft Failure
EP0249502A2 (en) Soluble immune suppressor factor and suppressor cells
Hall et al. Transplant Tolerance
Davenport et al. The role of the facilitating cell in the establishment of donor chimerism and transplantation tolerance
Gatti et al. History of hematopoietic stem cell transplantation
Olivares-Villagomez Control of autoimmune encephalomyelitis by CD4+ T cell receptor alpha-beta+ lymphocytes and their role in T cell homeostasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100611